In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...

The Muscular Dystrophy Association (MDA) is proud to announce the recipients of the 2026 MDA Legacy Awards, recognizing excellence in scientific and clinical research and saluting outstanding ...

Solid Biosciences (SLDB) stock rises as a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy reaches ...

Shares of  Regenxbio rose Monday in premarket trading after the company said its treatment for Duchenne muscular dystrophy delivered positive trial results, strengthening the case for a speedier ...

Highlights from the 2025 Muscular Dystrophy Association (MDA) Conference include clinical updates, expert insights, and breaking trial findings.

Muscle tissue damage appears when muscular dystrophy is induced in a mouse model (middle). But when researchers block the function of two genes that drive unwanted mitochondrial pore formation (right) ...

In research published in Developmental Medicine & Child Neurology , investigators developed a brief, reliable, and valid screening tool to help ...

PPMD extends its heartfelt thanks to all Race to End Duchenne runners, donors, and volunteers who made the 2026 Walt Disney World (R) Marathon Weekend a memorable and meaningful success. To learn more ...

The U.S. Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a certain ...

Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral ...

Sarepta (SRPT) projects $1.86B 2025 revenue and $898.7M from Elevidys amid an FDA boxed warning on liver failure risk.